Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kirstin C. Jensen"'
Autor:
Olivier Gevaert, Joseph B. Shrager, Sylvia K. Plevritis, Daniel L. Rubin, Charles T. Lau, Kirstin C. Jensen, Gerald J. Berry, Chuong D. Hoang, Sandy Napel, H. Henry Guo, Ann N. Leung, Amanda Khuong, Sebastian Echegaray
Publikováno v:
Scientific Reports
Molecular analysis of the mutation status for EGFR and KRAS are now routine in the management of non-small cell lung cancer. Radiogenomics, the linking of medical images with the genomic properties of human tumors, provides exciting opportunities for
Autor:
Kirstin C. Jensen, Allison W. Kurian, Elizabeth A. Schackmann, Meredith A. Mills, Robert W. Carlson, James M. Ford, C. Rocha, Shaveta Vinayak, Barry M. Sherman, Melinda L. Telli, Bruce L. Daniel, A Blackwood-Chirchir, Charles Bradley, Patrick Flaherty, P-J Chang, Irene Wapnir, Jafi A. Lipson
Publikováno v:
Cancer Research. 71:P3-14
Background The combination of gemcitabine, platinum and inhibition of DNA repair results in synergistic chemosensitivity in triple-negative and BRCA1-deficient breast cancer cell lines. This study was designed to assess efficacy, safety and predictor
Autor:
Chris Neff, Alexander Gutin, Elisha Hughes, Shikha Bose, Anne-Renee Hartman, Victor Abkevich, James M. Ford, Shaveta Vinayak, Melinda L. Telli, Zaina Sangale, William Audeh, Joshua Jones, Kirstin C. Jensen, Jerry S. Lanchbury, Pei-Jen Chang, Richard J. Wenstrup, Kirsten Timms
Publikováno v:
Cancer Research. 75:P5-06
Background: Defects in the homologous recombination (HR) DNA repair pathway sensitize tumors to therapeutics that target this pathway. A significant proportion of triple negative breast cancers (TNBC) carry HR defects. Recently three DNA-based measur
Autor:
Shaveta Vinayak, Melinda L. Telli, Jerry S. Lanchbury, Kirstin C. Jensen, Victor Abkevich, Kirsten Timms, James M. Ford, A-R Hartman, A. Gutin
Publikováno v:
Cancer Research. 72:PD09-04
Background: BC that arises in BRCA1/2 mutation carriers is characterized by defective homologous recombination DNA repair. Given the clinical potential for DNA repair-targeted therapeutics, Myriad Genetics has developed a tumor DNA-based assay that c